These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Extrapyramidal symptoms resulting from risperidone use in a four year old child: A case report. Elahi E; Zia U; Bhutta OA; Andleeb S J Pak Med Assoc; 2018 Nov; 68(11):1719-1720. PubMed ID: 30410159 [TBL] [Abstract][Full Text] [Related]
29. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone. Windhaber J; Urbanits S; Grisold W Neurology; 2000 Apr; 54(7):1543-4. PubMed ID: 10751282 [No Abstract] [Full Text] [Related]
30. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal. Perenyi A; Gardos G; Samu I; Kallos M; Cole JO Clin Neuropharmacol; 1983 Mar; 6(1):55-61. PubMed ID: 6133613 [TBL] [Abstract][Full Text] [Related]
31. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Anand VS; Dewan MJ Ann Clin Psychiatry; 1996 Sep; 8(3):179-82. PubMed ID: 8899136 [TBL] [Abstract][Full Text] [Related]
32. Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Magnuson TM; Keller BK; Burke WJ Am J Psychiatry; 1998 Oct; 155(10):1458-9. PubMed ID: 9766783 [No Abstract] [Full Text] [Related]
33. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. van der Linden C; Bruggeman R; van Woerkom TC Mov Disord; 1994 Nov; 9(6):687-8. PubMed ID: 7531282 [No Abstract] [Full Text] [Related]
34. Risperidone: an analysis of the first three years in general use. Gutierrez-Esteinou R; Grebb JA Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340 [TBL] [Abstract][Full Text] [Related]
36. The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat. Zhang XR; Zhang ZJ; Jenkins TA; Cheng WR; Reynolds GP J Sex Med; 2011 Dec; 8(12):3345-53. PubMed ID: 20233290 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of risperidone in psychotic patients: an open study. Daradkeh TK; Reda F; Karim L J Int Med Res; 1996; 24(3):291-5. PubMed ID: 8725991 [TBL] [Abstract][Full Text] [Related]
38. Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Lu ML; Shen WW Ann Pharmacother; 2002; 36(7-8):1292; author reply 1292-3. PubMed ID: 12086567 [No Abstract] [Full Text] [Related]
39. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Kopala LC; Good KP; Honer WG J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011 [TBL] [Abstract][Full Text] [Related]
40. Extrapyramidal Symptoms as a Result of Risperidone Discontinuation During Combination Therapy with Methylphenidate in a Pediatric Patient. Pérez CA; Garcia SS; Yu RD J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):182. PubMed ID: 26871198 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]